Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BLCO
stocks logo

BLCO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.38B
+8.12%
0.359
+43.52%
1.21B
+6.59%
0.082
-217.14%
1.36B
+6.07%
0.171
+144.59%
Estimates Revision
The market is revising No Change the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 11.99%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.66%
In Past 3 Month
Stock Price
Go Up
up Image
+11.99%
In Past 3 Month
Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 16.10 USD with a low forecast of 13.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 16.10 USD with a low forecast of 13.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
8 Hold
1 Sell
Hold
Current: 16.810
sliders
Low
13.00
Averages
16.10
High
19.00
Current: 16.810
sliders
Low
13.00
Averages
16.10
High
19.00
Morgan Stanley
Overweight
maintain
$21
2025-12-03
New
Reason
Morgan Stanley
Price Target
$21
2025-12-03
New
maintain
Overweight
Reason
Morgan Stanley reiterated an Overweight rating and $21 price target on Bausch + Lomb (BLCO), saying its CVS (CVS) commercial agreement over Xiidra ending is probably a good thing. Given that such a move was well anticipated, the firm understands that management still expects Xiidra to grow revenues in 2026, and while total prescriptions will be lower, the revenue impact is very modest given the big gross tot net dynamics here on low actual pricing, the analyst tells investors in a research note. The firm added that Xiidra margins overall should move up, marking a solid signal around pricing discipline within the industry overall.
Morgan Stanley
Equal Weight -> Overweight
upgrade
$14 -> $21
2025-12-02
New
Reason
Morgan Stanley
Price Target
$14 -> $21
2025-12-02
New
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Bausch + Lomb to Overweight from Equal Weight with a price target of $21, up from $14.
Morgan Stanley
Equal Weight -> Overweight
upgrade
$14 -> $21
2025-12-02
New
Reason
Morgan Stanley
Price Target
$14 -> $21
2025-12-02
New
upgrade
Equal Weight -> Overweight
Reason
As previously reported, Morgan Stanley upgraded Bausch + Lomb to Overweight from Equal Weight with a price target of $21, up from $14. The firm believes that the company has the strongest pipeline within ophthalmology and represents up to a $7B per year opportunity with many of the products coming down the pipe "amongst the most interesting and disruptive within both ophthalmology and healthcare overall," the analyst tells investors. While noting that most of the pipeline is coming in 2028 and beyond, there are "several key assets that are noteworthy" with efficiency measures driving margins up shorter-term, creating "a compelling financial profile over the next 2-3 years," the analyst added.
RBC Capital
Outperform
maintain
$17 -> $19
2025-11-14
Reason
RBC Capital
Price Target
$17 -> $19
2025-11-14
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Bausch + Lomb to $19 from $17 and keeps an Outperform rating on the shares. The company's Investor Day highlighted the significant operating leverage within the business, while the management also emphasized its robust pipeline, pointing to a steady stream of product launches over the next decade and an estimated peak sales potential of $7B, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$16 -> $17
2025-10-31
Reason
Barclays
Price Target
$16 -> $17
2025-10-31
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Bausch + Lomb to $17 from $16 and keeps an Equal Weight rating on the shares. The firm updated the company's estimates to reflect the Q3 earnings beat.
H.C. Wainwright
Buy
maintain
$16 -> $17
2025-10-31
Reason
H.C. Wainwright
Price Target
$16 -> $17
2025-10-31
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Bausch + Lomb to $17 from $16 and keeps a Buy rating on the shares. The company reported a Q3 beat and reiterates its 2025 outlook, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bausch + Lomb Corp (BLCO.N) is 19.71, compared to its 5-year average forward P/E of 21.17. For a more detailed relative valuation and DCF analysis to assess Bausch + Lomb Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
21.17
Current PE
19.71
Overvalued PE
25.27
Undervalued PE
17.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.58
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.35
Undervalued EV/EBITDA
9.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.27
Current PS
0.00
Overvalued PS
1.49
Undervalued PS
1.04
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BLCO News & Events

Events Timeline

(ET)
2025-11-13
07:41:55
Bausch + Lomb reaffirms FY25 revenue forecast of $5.050B-$5.150B, aligning with consensus of $5.08B
select
2025-10-29 (ET)
2025-10-29
07:08:40
Bausch + Lomb confirms FY25 revenue forecast of $5.050B-$5.150B, aligning with consensus of $5.08B
select
2025-10-29
07:06:50
Bausch + Lomb announces Q3 adjusted earnings per share of 18 cents, surpassing consensus estimate of 16 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-03CNBC
Midday Stock Highlights: Maplebear, Boeing, Credo Technology, XPO, MongoDB, and Others

  • Market Reactions: Instacart's parent company, Maplebear, fell nearly 4% due to Amazon's announcement of "ultra-fast" grocery delivery, while Boeing rose 8% after securing a $104.4 million Navy contract and providing positive cash flow guidance for 2026.

  • Earnings Reports: MongoDB's shares surged 23% following strong third-quarter results, while United Natural Foods gained 9% after beating earnings expectations, despite revenue falling short.

  • Stock Upgrades and Downgrades: Several companies saw stock movements due to analyst ratings, including Cloudflare and Bausch + Lomb, which both received upgrades, leading to respective gains of 2% and 4%.

  • Significant Declines: Janux Therapeutics experienced a 47% drop after disappointing trial results, and Signet Jewelers fell 4% due to lower-than-expected fourth-quarter revenue guidance.

[object Object]
Preview
2.0
12-02CNBC
Premarket Stock Highlights: MongoDB, Strategy, Signet Jewelers, Credo, and Others Making Significant Moves

  • MongoDB's Strong Performance: MongoDB shares surged 24% after reporting adjusted earnings of $1.32 per share on $628 million in revenue, exceeding analyst expectations and raising full-year guidance.

  • Janux Therapeutics Decline: Janux Therapeutics' stock plummeted 41% due to disappointing early-stage data from its prostate cancer trial, which fell short of expectations.

  • Signet Jewelers' Disappointing Guidance: Signet Jewelers' shares dropped nearly 5% after providing lower-than-expected revenue guidance for the holiday quarter, despite beating third-quarter revenue expectations.

  • Positive Movements in Other Companies: United Natural Foods, Cloudflare, and Credo Technology saw stock increases following earnings beats and upgrades, while Six Flags and Teradyne also gained from analyst upgrades.

[object Object]
Preview
6.0
11-14Benzinga
RBC Capital Reaffirms Outperform Rating for Bausch & Lomb, Increases Price Target to C$19

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to equip traders with the necessary tools and information to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bausch + Lomb Corp (BLCO) stock price today?

The current price of BLCO is 16.81 USD — it has decreased -0.88 % in the last trading day.

arrow icon

What is Bausch + Lomb Corp (BLCO)'s business?

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

arrow icon

What is the price predicton of BLCO Stock?

Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 16.10 USD with a low forecast of 13.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bausch + Lomb Corp (BLCO)'s revenue for the last quarter?

Bausch + Lomb Corp revenue for the last quarter amounts to 1.28B USD, increased 7.11 % YoY.

arrow icon

What is Bausch + Lomb Corp (BLCO)'s earnings per share (EPS) for the last quarter?

Bausch + Lomb Corp. EPS for the last quarter amounts to -0.08 USD, decreased -900.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bausch + Lomb Corp (BLCO)'s fundamentals?

The market is revising No Change the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 11.99%.
arrow icon

How many employees does Bausch + Lomb Corp (BLCO). have?

Bausch + Lomb Corp (BLCO) has 13500 emplpoyees as of December 05 2025.

arrow icon

What is Bausch + Lomb Corp (BLCO) market cap?

Today BLCO has the market capitalization of 5.95B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free